Cardiac Pulmonary Function of Ticagrelor Patients Studied
Dyspnea a common side effect, but heart and lung function do not seem to be adversely affected
TUESDAY, July 6 (HealthDay News) -- Dyspnea is commonly reported by coronary artery disease (CAD) patients taking ticagrelor, but it does not appear to have a negative impact on cardiac or pulmonary function in these patients, according to research published in the July 13 issue of the Journal of the American College of Cardiology.
Robert F. Storey, M.D., of the University of Sheffield in the United Kingdom, and colleagues analyzed data on 123 patients with stable CAD taking aspirin and either ticagrelor, clopidogrel, or placebo (57, 54, and 12 patients, respectively).
The researchers found that more patients in the ticagrelor group reported dyspnea than in the clopidogrel or placebo groups, at 38.6, 9.3, and 8.3 percent, respectively; and three patients in the ticagrelor group discontinued the medication due to dyspnea. Eight of the 22 patients in the ticagrelor group experiencing dyspnea did so within 24 hours, and 17 did so within a week. No changes in cardiac or pulmonary functions were seen in any treatment group, including the patients on ticagrelor reporting dyspnea, from baseline through six weeks' follow-up.
"Ticagrelor treatment was not associated with any adverse changes in cardiac or pulmonary function after six weeks of treatment in this study of patients who were free of active lung disease at commencement of the study, including patients who had dyspnea during therapy. Further studies of ticagrelor in patients with active lung disease are now warranted," the authors conclude.
The research was funded by, and three authors are employees of, AstraZeneca; two other authors disclosed financial ties to AstraZeneca and other pharmaceutical and medical device companies.